Microbiome in drug resistance to colon cancer

Pandey, Kavita; Umar, Shahid

doi:10.1016/j.cophys.2021.100472

Cited by 10 publications

(9 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IAA and IAALD are produced through the catabolism of tryptophan by the gut microbes (Vujkovic-Cvijin et al, 2013 ). Increasing evidence implicates that alterations in the microbiome influence resistance to anticancer treatment, including conventional chemotherapy, immunotherapy, radiotherapy, and surgery (Pryor et al, 2020 ; Garajová et al, 2021 ; Pandey and Umar, 2021 ). The relationship between changes in the microbiome and response to NACT warrants further investigation.…”

Section: Discussionmentioning

confidence: 99%

Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

Irajizad

Vykoukal

et al. 2022

Front. Artif. Intell.

View full text Add to dashboard Cite

There is a need to identify biomarkers predictive of response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC). We previously obtained evidence that a polyamine signature in the blood is associated with TNBC development and progression. In this study, we evaluated whether plasma polyamines and other metabolites may identify TNBC patients who are less likely to respond to NACT. Pre-treatment plasma levels of acetylated polyamines were elevated in TNBC patients that had moderate to extensive tumor burden (RCB-II/III) following NACT compared to those that achieved a complete pathological response (pCR/RCB-0) or had minimal residual disease (RCB-I). We further applied artificial intelligence to comprehensive metabolic profiles to identify additional metabolites associated with treatment response. Using a deep learning model (DLM), a metabolite panel consisting of two polyamines as well as nine additional metabolites was developed for improved prediction of RCB-II/III. The DLM has potential clinical value for identifying TNBC patients who are unlikely to respond to NACT and who may benefit from other treatment modalities.

show abstract

Section: Discussionmentioning

confidence: 99%

Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

Irajizad

Vykoukal

et al. 2022

Front. Artif. Intell.

View full text Add to dashboard Cite

show abstract

“…It is also worth noting that the microbiome plays a crucial role in the development of antibiotic resistance [ 126 , 127 ]. Microbiota dysbiosis induced by antibiotic treatment contributes to the development of resistance that is often due to increased numbers of opportunistic bacteria secreting high levels of antimicrobial resistance genes [ 128 , 129 ].…”

Section: Antibiotic Use and Antimicrobial Resistance In Cancer Patientsmentioning

confidence: 99%

Bacterial Infections and Cancer: Exploring This Association And Its Implications for Cancer Patients

Yusuf

Sampath

Umar

2023

IJMS

Self Cite

View full text Add to dashboard Cite

Bacterial infections are common in the etiology of human diseases owing to the ubiquity of bacteria. Such infections promote the development of periodontal disease, bacterial pneumonia, typhoid, acute gastroenteritis, and diarrhea in susceptible hosts. These diseases may be resolved using antibiotics/antimicrobial therapy in some hosts. However, other hosts may be unable to eliminate the bacteria, allowing them to persist for long durations and significantly increasing the carrier's risk of developing cancer over time. Indeed, infectious pathogens are modifiable cancer risk factors, and through this comprehensive review, we highlight the complex relationship between bacterial infections and the development of several cancer types. For this review, searches were performed on the PubMed, Embase, and Web of Science databases encompassing the entirety of 2022. Based on our investigation, we found several critical associations, of which some are causative: Porphyromonas gingivalis and Fusobacterium nucleatum are associated with periodontal disease, Salmonella spp., Clostridium perfringens, Escherichia coli, Campylobacter spp., and Shigella are associated with gastroenteritis. Helicobacter pylori infection is implicated in the etiology of gastric cancer, and persistent Chlamydia infections present a risk factor for the development of cervical carcinoma, especially in patients with the human papillomavirus (HPV) coinfection. Salmonella typhi infections are linked with gallbladder cancer, and Chlamydia pneumoniae infection is implicated in lung cancer, etc. This knowledge helps identify the adaptation strategies used by bacteria to evade antibiotic/antimicrobial therapy. The article also sheds light on the role of antibiotics in cancer treatment, the consequences of their use, and strategies for limiting antibiotic resistance. Finally, the dual role of bacteria in cancer development as well as in cancer therapy is briefly discussed, as this is an area that may help to facilitate the development of novel microbe-based therapeutics as a means of securing improved outcomes.

show abstract

“…The gut microbiota can also influence the efficacy of chemotherapy by inducing CRC chemoresistance[ 175 ]. The mechanisms of development of chemoresistance under the influence of microbiota may be associated with a violation of autophagy mechanisms[ 166 ] or a change in the metabolism of chemotherapeutic drugs, for example, gemcitabine[ 176 ].…”

Section: Gut Microbiota and Crc Treatmentmentioning

confidence: 99%

Genetic heterogeneity of colorectal cancer and the microbiome

Сеньчукова¹

2023

World J Gastrointest Oncol

View full text Add to dashboard Cite

In 2020, the International Agency for Research on Cancer and the World Health Organization's GLOBOCAN database ranked colorectal cancer (CRC) as the third most common cancer in the world. Most cases of CRC (> 95%) are sporadic and develop from colorectal polyps that can progress to intramucosal carcinoma and CRC. Increasing evidence is accumulating that the gut microbiota can play a key role in the initiation and progression of CRC, as well as in the treatment of CRC, acting as an important metabolic and immunological regulator. Factors that may determine the microbiota role in CRC carcinogenesis include inflammation, changes in intestinal stem cell function, impact of bacterial metabolites on gut mucosa, accumulation of genetic mutations and other factors. In this review, I discuss the major mechanisms of the development of sporadic CRC, provide detailed characteristics of the bacteria that are most often associated with CRC, and analyze the role of the microbiome and microbial metabolites in inflammation initiation, activation of proliferative activity in intestinal epithelial and stem cells, and the development of genetic and epigenetic changes in CRC. I consider long-term studies in this direction to be very important, as they open up new opportunities for the treatment and prevention of CRC.

show abstract

Microbiome in drug resistance to colon cancer

Cited by 10 publications

References 63 publications

Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

Bacterial Infections and Cancer: Exploring This Association And Its Implications for Cancer Patients

Genetic heterogeneity of colorectal cancer and the microbiome

Contact Info

Product

Resources

About